Abstract:Non-alcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver disease worldwide. Caspase 8 and FADD-like apoptosis regulator (CFLAR) has been identified as a potent factor in mitigating non-alcoholic steatohepatitis (NASH) by inhibiting the N-terminal dimerization of apoptosis signal-regulating kinase 1 (ASK1). While arginine methyltransferase 1 (PRMT1) was previously reported to be associated with increased hepatic glucose production, its involvement in hepatic lipid metabolism remains largely unexplored. The interaction between PRMT1 and CFLAR and the methylation of CFLAR were verified by Co-IP and immunoblotting assays. Recombinant adenoviruses were generated for overexpression or knockdown of PRMT1 in hepatocytes. The role of PRMT1 in NAFLD was investigated in normal and high-fat diet-induced obese mice. In this study, we found a significant upregulation of PRMT1 and downregulation of CFLAR after 48h of fasting, while the latter significantly rebounded after 12h of refeeding. The expression of PRMT1 increased in the livers of mice fed a methionine choline-deficient (MCD) diet and in hepatocytes challenged with oleic acid (OA)/palmitic acid (PA). Overexpression of PRMT1 not only inhibited the expression of genes involved in fatty acid oxidation (FAO) and promoted the expression of genes involved in fatty acid synthesis (FAS), resulting in increased triglyceride accumulation in primary hepatocytes, but also enhanced the gluconeogenesis of primary hepatocytes. Conversely, knockdown of hepatic PRMT1 significantly alleviated MCD diet-induced hepatic lipid metabolism abnormalities and liver injury in vivo, possibly through the upregulation of CFLAR protein levels. Knockdown of PRMT1 suppressed the expression of genes related to FAS and enhanced the expression of genes involved in FAO, causing decreased triglyceride accumulation in OA/PA-treated primary hepatocytes in vitro. Although short-term overexpression of PRMT1 had no significant effect on hepatic triglyceride levels under physiological conditions, it resulted in increased serum triglyceride and fasting blood glucose levels in normal C57BL/6J mice. More importantly, PRMT1 was observed to interact with and methylate CFLAR, ultimately leading to its ubiquitination-mediated protein degradation. This process subsequently triggered the activation of c-Jun N-terminal kinase 1 (JNK1) and lipid deposition in primary hepatocytes. Together, these results suggested that PRMT1-mediated methylation of CFLAR plays a critical role in hepatic lipid metabolism. Targeting PRMT1 for drug design may represent a promising strategy for the treatment of NAFLD.

Targeting MRG15 for the Treatment of Nonalcoholic Steatohepatitis

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Significance of MR/OPN/HMGB1 Axis in NAFLD-associated Hepatic Fibrogenesis.

MRG15 orchestrates rhythmic epigenomic remodelling and controls hepatic lipid metabolism

Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis

Peroxisome Proliferator-Activated Receptor Γ Coactivator 1α Maintains NAD+ Bioavailability Protecting Against Steatohepatitis

The E3 Ubiquitin Ligase Ring Finger Protein 5 Ameliorates NASH Through Ubiquitin‐Mediated Degradation of 3‐Hydroxy‐3‐Methylglutaryl CoA Reductase Degradation Protein 1

Fatty liver disease: time to target CCR5?

Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in miceResearch in context

The Regulatory Impact of CFLAR Methylation Modification on Liver Lipid Metabolism

A Mineralocorticoid Receptor Deficiency in Myeloid Cells Reduces Liver Steatosis by Impairing Activation of CD8+ T Cells in a Nonalcoholic Steatohepatitis Mouse Model

Targeting Mitochondria-Located circRNA SCAR Alleviates NASH via Reducing mROS Output.

Emerging Roles of MRG15 in Liver Metabolic Diseases

RMRP inhibition prevents NAFLD progression in rats via regulating miR-206/PTPN1 axis

Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2

The role of C5aR1-mediated hepatic macrophage efferocytosis in NASH

RNA helicase DEAD‐box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling

Targeting hepatic macrophages for non-alcoholic fatty liver disease therapy

Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice.

Targeting Hepatic Mir-221/222 for Therapeutic Intervention of Nonalcoholic Steatohepatitis in Mice

A long‐acting FGF21 attenuates metabolic dysfunction‐associated steatohepatitis‐related fibrosis by modulating NR4A1‐mediated Ly6C phenotypic switch in macrophages